188 related articles for article (PubMed ID: 35491102)
21. Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.
Liu Q; Ding Z; Lan J; Wong G
Methods Mol Biol; 2022; 2410():193-208. PubMed ID: 34914048
[TBL] [Abstract][Full Text] [Related]
22. Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
Jamieson TR; Poutou J; Marius R; He X; Rezaei R; Azad T; Ilkow CS
J Vis Exp; 2021 Jun; (172):. PubMed ID: 34152313
[TBL] [Abstract][Full Text] [Related]
23. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
[TBL] [Abstract][Full Text] [Related]
24. BSL2-compliant lethal mouse model of SARS-CoV-2 and variants of concern to evaluate therapeutics targeting the Spike protein.
Manangeeswaran M; Ireland DDC; Thacker SG; Lee HN; Kelley-Baker L; Lewkowicz AP; Rothlauf PW; Cornejo Pontelli M; Bloyet LM; Eckhaus MA; Mendoza MI; Whelan S; Verthelyi D
Front Immunol; 2022; 13():919815. PubMed ID: 35967447
[TBL] [Abstract][Full Text] [Related]
25. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.
Li H; Zhao C; Zhang Y; Yuan F; Zhang Q; Shi X; Zhang L; Qin C; Zheng A
Emerg Microbes Infect; 2020 Dec; 9(1):2269-2277. PubMed ID: 32990161
[TBL] [Abstract][Full Text] [Related]
26. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
J Virol; 2021 May; 95(11):. PubMed ID: 33727331
[TBL] [Abstract][Full Text] [Related]
27. Generating vesicular stomatitis virus pseudotype bearing the severe acute respiratory syndrome coronavirus spike envelope glycoprotein for rapid and safe neutralization test or cell-entry assay.
Ge J; Wen Z; Wang X; Hu S; Liu Y; Kong X; Chen H; Bu Z
Ann N Y Acad Sci; 2006 Oct; 1081(1):246-8. PubMed ID: 17135519
[TBL] [Abstract][Full Text] [Related]
28. Whole genome CRISPR screening strategy to identify genes contributing to SARS-CoV-2 spike and VSV-G mediated entry.
Hossain MS; Kerkvliet JG; Hoppe AD
J Med Virol; 2023 Sep; 95(9):e29087. PubMed ID: 37707319
[TBL] [Abstract][Full Text] [Related]
29. Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol.
Condor Capcha JM; Lambert G; Dykxhoorn DM; Salerno AG; Hare JM; Whitt MA; Pahwa S; Jayaweera DT; Shehadeh LA
Front Cardiovasc Med; 2020; 7():618651. PubMed ID: 33521067
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus.
Fu X; Tao L; Zhang X
Mol Ther Methods Clin Dev; 2021 Mar; 20():350-356. PubMed ID: 33521163
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.
Carpinteiro A; Edwards MJ; Hoffmann M; Kochs G; Gripp B; Weigang S; Adams C; Carpinteiro E; Gulbins A; Keitsch S; Sehl C; Soddemann M; Wilker B; Kamler M; Bertsch T; Lang KS; Patel S; Wilson GC; Walter S; Hengel H; Pöhlmann S; Lang PA; Kornhuber J; Becker KA; Ahmad SA; Fassbender K; Gulbins E
Cell Rep Med; 2020 Nov; 1(8):100142. PubMed ID: 33163980
[TBL] [Abstract][Full Text] [Related]
32. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
Xu C; Wang A; Geng K; Honnen W; Wang X; Bruiners N; Singh S; Ferrara F; D'Angelo S; Bradbury ARM; Gennaro ML; Liu D; Pinter A; Chang TL
Viruses; 2021 May; 13(6):. PubMed ID: 34064066
[TBL] [Abstract][Full Text] [Related]
33. Establishment of Replication Deficient Vesicular Stomatitis Virus for Studies of PEDV Spike-Mediated Cell Entry and Its Inhibition.
Luo H; Lv L; Yi J; Zhou Y; Liu C
Microorganisms; 2023 Aug; 11(8):. PubMed ID: 37630636
[TBL] [Abstract][Full Text] [Related]
34. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.
Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH
Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550
[TBL] [Abstract][Full Text] [Related]
35. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters.
O'Donnell KL; Clancy CS; Griffin AJ; Shifflett K; Gourdine T; Thomas T; Long CM; Furuyama W; Marzi A
Front Immunol; 2021; 12():788235. PubMed ID: 35069564
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
37. Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.
Rosen O; Jayson A; Goldvaser M; Dor E; Monash A; Levin L; Cherry L; Lupu E; Natan N; Girshengorn M; Epstein E
Biotechnol Bioeng; 2022 Jul; 119(7):1839-1848. PubMed ID: 35319097
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
[TBL] [Abstract][Full Text] [Related]
39. Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.
Tang H; Gao L; Wu Z; Meng F; Zhao X; Shao Y; Shi X; Qiao S; An J; Du X; Qin FX
Front Cell Infect Microbiol; 2021; 11():720357. PubMed ID: 34722330
[TBL] [Abstract][Full Text] [Related]
40. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
